Osimertinib

Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.

CHICAGO — Healio spoke with Karen L. Reckamp, MD, on updated findings from the ADAURA trial presented at ASCO Annual Meeting.

CHICAGO — MET status by immunohistochemistry may predict how patients with osimertinib-treated EGFR-mutated non-small lung cancer will respond to subsequent combination therapy, according to findings presented at ASCO Annual Meeting.

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.

CHICAGO — A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria.

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADAURA trial presented at ASCO Annual Meeting.

CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.

First-line osimertinib plus chemotherapy extended PFS compared with osimertinib alone for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, topline results of the randomized phase 3 FLAURA2 trial showed.

In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.

Osimertinib extended DFS and reduced risk for recurrence among patients with resected EGFR-mutated non-small cell lung cancer, according to an updated analysis of data from the phase 3 ADAURA trial published in Journal of Clinical Oncology.